A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
Thanks to the comprehensive AMD Excellence training program from MacuLogix, each staff member - from the front desk and optical to technicians and billing - understands the important role they play in AMD care.
Now that we are using the AdaptDx to diagnose AMD earlier and actively manage disease progression, I’m confident we will improve outcomes in both eyes by catching CNV before significant vision loss occurs.
I’ve had fellow practitioners that have said, ‘I didn’t know this was out here’ about the AdaptDx. But once you see the science behind the device, you realize what it can do for your practice and AMD patients. It becomes clear how much easier it is to detect AMD earlier and to track its progression. We as Vision Source doctors tend to practice more comprehensive eye care over just refractions and this becomes increasingly effortless with the AdaptDx dark adaptometer.
The AdaptDx is simple for the patient and takes little staff training to become proficient at administering. Analyzing the data by the doctor only takes seconds and is very simple to interpret. This allows more time to discuss with the patient the results and the plan of action when needed.
The impact of the AdaptDx on my patient care and practice revenue has been phenomenal!
The test is a great benchmark that I use to determine depth of the disease and how soon the patient needs to return for another visit.
It would be unimaginable nowadays to diagnose glaucoma without both structural and functional testing. With today’s technology, the same can be said for AMD as functional testing complements structural findings for the earliest indications of the disease
If you had a crystal ball to predict glaucoma, diabetic retinopathy or AMD would you not take advantage of it? We have early diagnostic strategies for all three. Ganglion cell loss and capillary density reduction are sentinels for glaucoma and DR, respectively. Impaired dark adaptation is the gold standard bio marker for sub clinical AMD. The AdaptDx is the FDA-cleared instrument for this important measurement.
The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.
The AdaptDx is a complete paradigm shift in the management and vision loss prevention of AMD. We no longer have the "watch & wait" approach with AMD. Our new proactive approach to this sight threatening disease is utilizing the AdaptDx to diagnose AMD due to physiological changes that occur YEARS before any drusen and structural changes are visible. Then, we start patients on a treatment plan and follow up care significantly earlier, resulting in greatly improved outcomes for our patients!!